MedTrace Logo

Voronistat in Pediatric Patients With Drug Resistant Epilepsy

NCT03894826 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2019-03-29

No results posted yet for this study

Summary

The study evaluates the safety, tolerability, and efficacy of Vorinostat in addition to standard of care anti-epileptic drugs in pediatric patients with medically refractory epilepsy. All participants entering the treatment phase will receive Vorinostat.

Conditions

  • Refractory Epilepsy

Interventions

DRUG

Vorinostat 100 MG

Vorinostat administered by mouth, once daily at a dose of 230 mg/m2/day for a total of 6 weeks

Sponsors & Collaborators

  • University of Calgary

    lead OTHER

Principal Investigators

  • Jong Rho, MD · University of Calgary

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
17 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-12-10
Primary Completion
2020-04-30
Completion
2020-10-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03894826 on ClinicalTrials.gov